Life Science & Biotech

Judge rejects Guidant's defibrillator plea deal

April 27, 2010
Bloomberg News
A federal judge has rejected Guidant Corp.'s guilty plea to charges it hid defects in heart defibrillators, after some doctors and patients complained about the $296 million deal.
More

Medical device startup FlowCo enlists Guidant alums

April 24, 2010
Chris O'Malley
The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement product to market as soon as 2011.
More

Lilly to pay $400M to repurchase Cymbalta rights

April 19, 2010
Bloomberg News
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European partner Boehringer Ingelheim for an initial payment of $400 million.
More

Lilly sues Hospira over generic version of Gemzar

March 24, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the cancer drug Gemzar before a patent on the medicine expires in 2013.
More

Ariad loses $65M patent appeal against Eli Lilly

March 22, 2010
Bloomberg News
Monday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis drug Evista and sepsis medicine Xigris.
More

FDA says 'not yet' on Lilly's once-weekly Byetta

March 15, 2010
J.K. Wall
Regulators won't require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling, manufacturing processes.
More

Eli Lilly to buy European rights to Pfizer animal products

March 8, 2010
Scott Olson
The acquisition will benefit Elanco, Lilly's animal health division in Greenfield, which has become increasingly important to Lilly as it braces for patent-protection losses.
More

Dow AgroSciences considered expansion elsewhere

March 5, 2010
Peter Schnitzler
Agricultural biotech firm hired a site-selection consultant and considered other cities around the world for its $340 million expansion.
More

Dow Agro plans $340M expansion, 577 new jobs

March 4, 2010
Peter Schnitzler
The investment will greatly expand the company's research and development capacity and is a major win for the Indiana life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
More

Cornelius to retire as Bristol-Myers Squibb CEO

March 3, 2010
 IBJ Staff and Associated Press
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
More

Dow Agro plans 'major' expansion announcement

March 3, 2010
Peter Schnitzler
Local Dow Chemical subsidiary expects to launch five new biotech products by 2012.
More

Lilly to shift more employees to Covance

February 26, 2010
J.K. Wall
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
More

Indiana companies that serve pharmaceutical industry grew in 2009

February 20, 2010
 IBJ Staff
The firms continued to grow over the last year but face increasing challenges, according to a new report by Indianapolis-based life sciences trade group BioCrossroads.
More

Vortek Surgical moving HQ to Brownsburg, adding 60 jobs

February 18, 2010
 IBJ Staff
Indianapolis-based Vortek Surgical LLC will relocate to Brownsburg, expanding its headquarters, manufacturing and distribution operations and creating more than 60 jobs in the next three years.
More

Bioanalytical Systems reports quarterly loss

February 17, 2010
Bioanalytical Systems Inc., a West Lafayette-based life sciences contract research firm, on Wednesday reported a loss of $1.4 million for its fiscal first quarter.
More

Dow Agro CEO says pipeline of products strong

February 10, 2010
Dow AgroSciences CEO Antonio Galindez told investors Wednesday morning that the company plans to launch five products by 2013 that could increase annual revenue by $800 million.
More

Report: State's pharmaceutical contractors continue to grow

February 10, 2010
A report set to be released Wednesday by local life sciences industry group BioCrossroads says Indiana companies providing contract pharmaceutical research and manufacturing services are weathering the economic downturn and are growing.
More

Health care venture capital swoons in Indy, holds steady statewide

February 6, 2010
 IBJ Staff
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
More

Health firms still attracting venture capital

February 3, 2010
J.K. Wall
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009. That trend hit Indianapolis, but the rest of the state actually saw an increase.
More

Dow AgroSciences profit falls despite revenue increase

February 2, 2010
 IBJ Staff
Indianapolis-based Dow AgroSciences said Tuesday it posted a profit of $69 million in the fourth quarter, down 19 percent from the prior year because of increased research and development spending and higher administrative expenses. Revenue was up 17 percent.
More

City of Greenwood might fund launch of insulin makerRestricted Content

January 30, 2010
Kathleen McLaughlin
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin, a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
More

TechPoint accepting nominations for Mira technology awards

January 23, 2010
 IBJ Staff
The awards are meant to showcase Indiana's high-tech success stories and raise the profile of the tech community.
More

Dow Agro in legal skirmish over canola oil

January 14, 2010
Bloomberg News
Indianapolis-based Dow AgroSciences LLC has sued Cooper Industries Plc in an effort to clarify its rights to make a canola-based fluid used in electrical transformers.
More

Entrepreneur says quality of venture capital as important as quantity

January 2, 2010
 IBJ Staff
Jim Pearson knows a thing or two about raising money from venture capitalists. And he has some advice for BioCrossroads: Teach entrepreneurs the value of money.
More

First Indiana Future Fund off to a slow startRestricted Content

December 19, 2009
Peter Schnitzler
More than half of the venture capital fund's original investors took a pass on its $58 million successor, the newly launched INext.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. If I were a developer I would be looking at the Fountain Square and Fletcher Place neighborhoods instead of Broad Ripple. I would avoid the dysfunctional BRVA with all of their headaches. It's like deciding between a Blackberry or an iPhone 5s smartphone. BR is greatly in need of updates. It has become stale and outdated. Whereas Fountain Square, Fletcher Place and Mass Ave have become the "new" Broad Ripples. Every time I see people on the strip in BR on the weekend I want to ask them, "How is it you are not familiar with Fountain Square or Mass Ave? You have choices and you choose BR?" Long vacant storefronts like the old Scholar's Inn Bake House and ZA, both on prominent corners, hurt the village's image. Many business on the strip could use updated facades. Cigarette butt covered sidewalks and graffiti covered walls don't help either. The whole strip just looks like it needs to be power washed. I know there is more to the BRV than the 700-1100 blocks of Broad Ripple Ave, but that is what people see when they think of BR. It will always be a nice place live, but is quickly becoming a not-so-nice place to visit.

  2. I sure hope so and would gladly join a law suit against them. They flat out rob people and their little punk scam artist telephone losers actually enjoy it. I would love to run into one of them some day!!

  3. Biggest scam ever!! Took 307 out of my bank ac count. Never received a single call! They prey on new small business and flat out rob them! Do not sign up with these thieves. I filed a complaint with the ftc. I suggest doing the same ic they robbed you too.

  4. Woohoo! We're #200!!! Absolutely disgusting. Bring on the congestion. Indianapolis NEEDS it.

  5. So Westfield invested about $30M in developing Grand Park and attendance to date is good enough that local hotel can't meet the demand. Carmel invested $180M in the Palladium - which generates zero hotel demand for its casino acts. Which Mayor made the better decision?

ADVERTISEMENT